GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody And Cellular Immunity In Immunocompromised Patients
Portfolio Pulse from Benzinga Newsdesk
GeoVax Labs, Inc. (NASDAQ:GOVX) has published data from the ongoing Phase 2 trial of its next-generation COVID-19 vaccine (GEO-CM04S1), demonstrating potent antibody and cellular immunity in immunocompromised patients. The vaccine is being compared to the Pfizer/BioNTech or Moderna mRNA-based vaccines in patients with compromised immune systems. The data indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing potent humoral (antibody) and cellular (T cell) responses, including neutralizing antibodies against SARS-CoV-2 ancestral virus and variants of concern.
September 19, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeoVax's ongoing Phase 2 trial data shows its next-generation COVID-19 vaccine (GEO-CM04S1) induces potent immunity in immunocompromised patients. This could potentially increase the demand for GeoVax's vaccine, positively impacting its stock price.
The positive results from the Phase 2 trial of GeoVax's next-generation COVID-19 vaccine indicate its effectiveness in immunocompromised patients. This could potentially increase the demand for the vaccine, especially among patients for whom other vaccines have proven less effective. This increased demand could lead to higher revenues for GeoVax, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100